A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

Prior treatment

• Subject with existence of any surgical or medical condition that, in the judgment of the Investigator, might interfere with the absorption, distribution, metabolism or excretion of the investigational product.
• Subject is unwilling to abstain from vigorous exercise from 48 hours prior to admission until the Follow-up visit.
• History of alcohol abuse as judged by the Investigator within approximately 1 year prior to Screening.
• History of regular use (defined as ≥ 10 cigarettes per day) of nicotine-containing products (including but not limited to cigarettes, e-cigarettes, pipe, chewing tobacco, nicotine patch or gum) or vaping products within 6 weeks prior to check-in for the first In-house Period.

Other illness

• Subjects with a history of any serious adverse reaction or hypersensitivity to study drug components (includes GLP-1, GIP, glucagon analogs) or have contraindicating diseases.
• Subjects with confirmed type 1 or type 2 diabetes.

Age

• Active or untreated malignancy or has been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for \< 5 years.

Other

• Subject is unwilling to avoid consumption of coffee and caffeine-containing beverages within from 24 hours before each study visit and while subjects are confined to the study center.

• Female and male adults, ages ≥ 18 and ≤ 65 years.
• Part A: Healthy subjects with body mass index (BMI) ≥ 20.0 kg/m2 and ≤ 27 kg/m2.
  • Part B: Obese subjects with BMI ≥ 30.0 kg/m2 and ≤ 45.0 kg/m2 with a stable body weight for 3 months prior to screening (defined as change \< 5%).
• HbA1c \< 6.5 % \[based on American Diabetes Association, 2023\].
• Female subjects must be non-pregnant and non-lactating.
• Subjects must be able to provide written informed consent and are willing to follow study procedures and commitment to the study duration.